Suppr超能文献

肾移植受者的类固醇避免或停用

Steroid avoidance or withdrawal for kidney transplant recipients.

作者信息

Haller Maria C, Royuela Ana, Nagler Evi V, Pascual Julio, Webster Angela C

机构信息

Section for Clinical Biometrics, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University Vienna, Spitalgasse 23, Vienna, Austria, A-1090.

出版信息

Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD005632. doi: 10.1002/14651858.CD005632.pub3.

Abstract

BACKGROUND

Steroid-sparing strategies have been attempted in recent decades to avoid morbidity from long-term steroid intake among kidney transplant recipients. Previous systematic reviews of steroid withdrawal after kidney transplantation have shown a significant increase in acute rejection. There are various protocols to withdraw steroids after kidney transplantation and their possible benefits or harms are subject to systematic review. This is an update of a review first published in 2009.

OBJECTIVES

To evaluate the benefits and harms of steroid withdrawal or avoidance for kidney transplant recipients.

SEARCH METHODS

We searched the Cochrane Kidney and Transplant Specialised Register to 15 February 2016 through contact with the Information Specialist using search terms relevant to this review.

SELECTION CRITERIA

All randomised and quasi-randomised controlled trials (RCTs) in which steroids were avoided or withdrawn at any time point after kidney transplantation were included.

DATA COLLECTION AND ANALYSIS

Assessment of risk of bias and data extraction was performed by two authors independently and disagreement resolved by discussion. Statistical analyses were performed using the random-effects model and dichotomous outcomes were reported as relative risk (RR) and continuous outcomes as mean difference (MD) with 95% confidence intervals.

MAIN RESULTS

We included 48 studies (224 reports) that involved 7803 randomised participants. Of these, three studies were conducted in children (346 participants). The 2009 review included 30 studies (94 reports, 5949 participants). Risk of bias was assessed as low for sequence generation in 19 studies and allocation concealment in 14 studies. Incomplete outcome data were adequately addressed in 22 studies and 37 were free of selective reporting.The 48 included studies evaluated three different comparisons: steroid avoidance or withdrawal compared with steroid maintenance, and steroid avoidance compared with steroid withdrawal. For the adult studies there was no significant difference in patient mortality either in studies comparing steroid withdrawal versus steroid maintenance (10 studies, 1913 participants, death at one year post transplantation: RR 0.68, 95% CI 0.36 to 1.30) or in studies comparing steroid avoidance versus steroid maintenance (10 studies, 1462 participants, death at one year after transplantation: RR 0.96, 95% CI 0.52 to 1.80). Similarly no significant difference in graft loss was found comparing steroid withdrawal versus steroid maintenance (8 studies, 1817 participants, graft loss excluding death with functioning graft at one year after transplantation: RR 1.17, 95% CI 0.72 to 1.92) and comparing steroid avoidance versus steroid maintenance (7 studies, 1211 participants, graft loss excluding death with functioning graft at one year after transplantation: RR 1.09, 95% CI 0.64 to 1.86). The risk of acute rejection significantly increased in patients treated with steroids for less than 14 days after transplantation (7 studies, 835 participants: RR 1.58, 95% CI 1.08 to 2.30) and in patients who were withdrawn from steroids at a later time point after transplantation (10 studies, 1913 participants, RR 1.77, 95% CI 1.20 to 2.61). There was no evidence to suggest a difference in harmful events, such as infection and malignancy, in adult kidney transplant recipients. The effect of steroid withdrawal in children is unclear.

AUTHORS' CONCLUSIONS: This updated review increases the evidence that steroid avoidance and withdrawal after kidney transplantation significantly increase the risk of acute rejection. There was no evidence to suggest a difference in patient mortality or graft loss up to five year after transplantation, but long-term consequences of steroid avoidance and withdrawal remain unclear until today, because prospective long-term studies have not been conducted.

摘要

背景

近几十年来,人们一直在尝试采用减少类固醇使用的策略,以避免肾移植受者因长期服用类固醇而出现并发症。先前关于肾移植后停用类固醇的系统评价显示,急性排斥反应显著增加。肾移植后有多种停用类固醇的方案,其可能的益处或危害有待系统评价。这是对2009年首次发表的一篇综述的更新。

目的

评估肾移植受者停用或避免使用类固醇的益处和危害。

检索方法

我们通过与信息专家联系,使用与本综述相关的检索词,检索了截至2016年2月15日的Cochrane肾脏与移植专业注册库。

入选标准

纳入所有在肾移植后任何时间点避免或停用类固醇的随机和半随机对照试验(RCT)。

数据收集与分析

由两位作者独立进行偏倚风险评估和数据提取,如有分歧通过讨论解决。采用随机效应模型进行统计分析,二分法结局以相对风险(RR)报告,连续结局以平均差(MD)报告,并给出95%置信区间。

主要结果

我们纳入了48项研究(224篇报告),涉及7803名随机参与者。其中,3项研究是在儿童中进行的(346名参与者)。2009年的综述纳入了30项研究(94篇报告,5949名参与者)。19项研究的序列生成和14项研究的分配隐藏的偏倚风险评估为低。22项研究对不完整结局数据进行了充分处理,37项研究无选择性报告。纳入的48项研究评估了三种不同的比较:避免或停用类固醇与维持使用类固醇,以及避免使用类固醇与停用类固醇。对于成人研究,在比较停用类固醇与维持使用类固醇的研究中(10项研究,1913名参与者,移植后一年死亡:RR 0.68,95%CI 0.36至1.30),以及在比较避免使用类固醇与维持使用类固醇的研究中(10项研究,1462名参与者,移植后一年死亡:RR 0.96,95%CI 0.52至1.80),患者死亡率均无显著差异。同样地,在比较停用类固醇与维持使用类固醇的研究中(8项研究,1817名参与者,移植后一年不包括死亡且移植肾功能良好的移植物丢失:RR 1.17,95%CI 0.72至1.92),以及在比较避免使用类固醇与维持使用类固醇的研究中(7项研究,1211名参与者,移植后一年不包括死亡且移植肾功能良好的移植物丢失:RR 1.09,95%CI 0.64至1.86),移植物丢失均无显著差异。移植后接受类固醇治疗少于14天的患者(7项研究,835名参与者:RR 1.58,95%CI 1.08至2.30)以及在移植后较晚时间点停用类固醇的患者(10项研究,1913名参与者,RR 1.77,95%CI 1.20至2.61),急性排斥反应的风险显著增加。没有证据表明成年肾移植受者在感染和恶性肿瘤等有害事件方面存在差异。儿童停用类固醇的效果尚不清楚。

作者结论

本次更新后的综述增加了证据,表明肾移植后避免和停用类固醇会显著增加急性排斥反应的风险。没有证据表明移植后五年内患者死亡率或移植物丢失存在差异,但由于尚未进行前瞻性长期研究,避免和停用类固醇的长期后果至今仍不清楚。

相似文献

1
Steroid avoidance or withdrawal for kidney transplant recipients.
Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD005632. doi: 10.1002/14651858.CD005632.pub3.
2
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Cochrane Database Syst Rev. 2017 Jul 20;7(7):CD004756. doi: 10.1002/14651858.CD004756.pub4.
3
Steroid avoidance or withdrawal for kidney transplant recipients.
Cochrane Database Syst Rev. 2009 Jan 21(1):CD005632. doi: 10.1002/14651858.CD005632.pub2.
4
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Cochrane Database Syst Rev. 2017 Jan 11;1(1):CD004759. doi: 10.1002/14651858.CD004759.pub2.
5
Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Cochrane Database Syst Rev. 2017 Jul 21;7(7):CD006750. doi: 10.1002/14651858.CD006750.pub2.
6
Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.
Cochrane Database Syst Rev. 2018 Apr 9;4(4):CD007606. doi: 10.1002/14651858.CD007606.pub4.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
10
Interleukin 2 receptor antagonists for kidney transplant recipients.
Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD003897. doi: 10.1002/14651858.CD003897.pub3.

引用本文的文献

1
Impact of Corticosteroid-Free Regimen on Interstitial Fibrosis Following Kidney Transplantation.
Kidney Int Rep. 2025 Apr 6;10(7):2222-2232. doi: 10.1016/j.ekir.2025.04.004. eCollection 2025 Jul.
2
3
Novel insights and an updated review of metabolic syndrome in immune-mediated organ transplant rejection.
Front Immunol. 2025 Apr 22;16:1580369. doi: 10.3389/fimmu.2025.1580369. eCollection 2025.
4
Posttransplantation diabetes mellitus (PTDM): pharmacological aspects and genetic predispositions.
Pharmacogenomics. 2024;25(16-18):707-718. doi: 10.1080/14622416.2025.2470613. Epub 2025 Feb 28.
5
Early Steroid Withdrawal in Kidney Transplant Recipients: PRO.
Kidney360. 2025 Feb 1;6(2):191-193. doi: 10.34067/KID.0000000000000326.
6
Early Steroid Withdrawal in Kidney Transplant Recipients: CON.
Kidney360. 2025 Feb 1;6(2):187-190. doi: 10.34067/KID.0000000000000323.
9
Early steroid withdrawal and kidney transplant outcomes in first-transplant and retransplant recipients.
Nephrol Dial Transplant. 2025 Apr 1;40(4):662-670. doi: 10.1093/ndt/gfae218.
10
Predicting outcomes after kidney transplantation: Can Pareto's rules help us to do so?
World J Transplant. 2024 Mar 18;14(1):90149. doi: 10.5500/wjt.v14.i1.90149.

本文引用的文献

1
Long-term study of steroid avoidance in renal transplant patients: a single-center experience.
Transplant Proc. 2015 May;47(4):1099-104. doi: 10.1016/j.transproceed.2014.11.063.
2
New-Onset Diabetes After Transplantation: Results From a Double-Blind Early Corticosteroid Withdrawal Trial.
Am J Transplant. 2015 Jul;15(7):1982-90. doi: 10.1111/ajt.13247. Epub 2015 Apr 16.
4
A randomized trial of everolimus and low-dose cyclosporine in renal transplantation: with or without steroids?
Transplant Proc. 2014 Dec;46(10):3375-82. doi: 10.1016/j.transproceed.2014.05.087.
6
Interleukin-2 receptor antagonist therapy leads to increased tacrolimus levels after kidney transplantation.
Ther Drug Monit. 2015 Apr;37(2):206-13. doi: 10.1097/FTD.0000000000000125.
7
15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation.
Transplantation. 2014 Jul 15;98(1):47-53. doi: 10.1097/01.TP.0000442774.46133.71.
9
The clinical impact of humoral immunity in pediatric renal transplantation.
J Am Soc Nephrol. 2013 Mar;24(4):655-64. doi: 10.1681/ASN.2012070663. Epub 2013 Feb 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验